News

Deal Announcements

AlloCure Scores Series A Venture Capital Round

Monday, July 7, 2008 6:03:00 AM PDT | VentureDeal Staff
Salt Lake City, Utah -- Medical device company AlloCure announced that it has secured $14.5 million in series A venture capital funding.

AlloCure is developing cell therapies for what it says is a novel and proprietary class of biological therapeutics.  It's most advanced therapies target acute kidney injury, kidney transplantation and multi-organ failure.

SV Life Sciences led the round, which included Novo A/S.  The company said it would use the new investment to fund its acute kidney disease therapy through phase 2 clinical trials over the next three years.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1